Proposing oligo-recurrence criteria in pancreatic ductal adenocarcinoma: A stratified analysis of locoregional treatment benefits
Open Access
- 21 April 2025
- journal article
- Published by Elsevier in Pancreatology
- Vol. 25 (6) , 889-897
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- A comprehensive approach to defining the cutoff value of oligometastasis in head and neck squamous cell carcinomaCancer, 2024
- Long‐term treatment outcomes in gastric cancer with oligometastasisAnnals of Gastroenterological Surgery, 2023
- Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal AdenocarcinomaJAMA Network Open, 2022
- Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysisJournal of Hepato-Biliary-Pancreatic Sciences, 2022
- Pancreatic CancerJAMA, 2021
- Primary Recurrence in the Lung is Related to Favorable Prognosis in Patients with Pancreatic Cancer and Postoperative RecurrenceWorld Journal of Surgery, 2017
- Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancerStrahlentherapie und Onkologie, 2014
- Long‐term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancerCancer, 2011
- On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival dataStatistics in Medicine, 2011
- Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic CancerJAMA, 2007